Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Schild SE et al. - The use of RT requires careful planning resulting in the administration of a tumoricidal dose to the tumor cells with adequate sparing of normal tissues. RT has been used for primary therapy, postresection adjuvant therapy and palliation of symptomatic melanoma. Curative RT has been given for uveal melanoma yielding patient survival equivalent to enucleation. RT has been administered to patients with unresectable disease yielding relatively favorable results. As an adjuvant therapy postoperatively, RT has been used selectively to improve local disease control. Finally, RT is used successfully as a palliative maneuver for symptoms related to distant metastatic melanoma in patients with incurable disease.

Related Articles

Loss of SNF5 expression correlates with poor patient survival in melanoma
Clinical Cancer Research, 10/12/09    Relevance Score: 97%

Slow-growing melanoma: a dermoscopy follow-up study
British Journal of Dermatology, 10/05/09    Relevance Score: 93%

Dormancy of metastatic melanoma
Pigment Cell & Melanoma Research, 11/11/09    Relevance Score: 91%

ADAM10 Is Upregulated in Melanoma Metastasis Compared with Primary Melanoma
Journal of Investigative Dermatology, 11/03/09    Relevance Score: 91%

KIT as a Therapeutic Target in Melanoma
Journal of Investigative Dermatology, 10/23/09    Relevance Score: 90%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address